LitAlert ~~

    • An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer.
    • Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, Yin R, Wu X, Yao S, Gu K, Zhang H, Li G, Pan H, Wu Q, An R, Yang X, Zhu YP, wan X, Duan W, Xiong J, Guo H, Lou G, Wang J, Hu WJ, Zhang X, Meng Y, Zhang B, Wang Y, Wang QR, Wu L.
    • Clin Cancer Res. 2021 Feb 8. doi: 10.1158/1078-0432.CCR-20-3546. Epub ahead of print.
    • Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    • Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G.
    • Drug Resist Updat. 2021 Jan 16:100744. doi: 10.1016/j.drup.2021.100744. Epub ahead of print.
    • Review